Vancouver, BC, April 10, 2018--(T-Net)--Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that it has entered into a first amending agreement to its amended and restated term loan agreement with CRG Servicing LLC managed funds dated May 11, 2017 to provide for certain adjustments to the financial covenants with respect to minimum revenue.

Under the terms of the amended agreement, CRG has waived its right to receive payment of certain cash compensation of up to $6 million dollars that would have been required under the original agreement and has agreed to permit the divestiture of Cardiome's Canadian business portfolio under the proposed transaction with Cipher Pharmaceuticals.

In consideration for entering into the Amended Agreement, CRG received 800,000 common share purchase warrants with an exercise price of US$2.50. The Warrants are subject to a four-month hold period and are exercisable until March 27, 2023.

About Cardiome Pharma Corp.

Cardiome is traded on the NASDAQ Capital Market (CRME) and the Toronto Stock Exchange (COM). For more information, please visit our web site at www.cardiome.com.

Forward-Looking Statement Disclaimer

Certain statements in this news release contain forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation ("forward-looking statements") that may not be based on historical fact, including without limitation statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements.

A discussion of the risks and uncertainties facing Cardiome are discussed in our most recent annual and quarterly reports and detailed from time to time in our other filings with the Securities and Exchange Commission ("SEC") available at www.sec.gov and the Canadian securities regulatory authorities at www.sedar.com. All of the risks and certainties disclosed in these filings are hereby incorporated by reference in their entirety. While Cardiome makes these forward-looking statements in good faith, given these risks, uncertainties and factors, you are cautioned not to place undue reliance on any forward-looking statements made in this press release. All forward-looking statements made herein are based on our current expectations and we undertake no obligation to revise or update such forward-looking statements to reflect subsequent events or circumstances, except as required by law.
[null, {"document_url": "http://bctechnology.com/news/2018/4/10/Cardiome-Announces-Amendment-to-Term-Loan-Agreement-with-CRG-Managed-Funds.cfm?profile_id=5679&id=38909&allmatches=1&company_list=Correvio%20Pharma%20Corp&posted=all&by_x=ins_date", "unformatted_src": "/tmp/news/C6E4BE9C74D51E579A7590AF93EED160D89E0FBB8B934CA558AA50B7C87C4F95.jpg", "src": "https://bctechnology.com/tmp/news/C6E4BE9C74D51E579A7590AF93EED160D89E0FBB8B934CA558AA50B7C87C4F95.jpg", "formatted_filename": "C E BE C D E A AF EED D E FBB B CA AA B C C F"}, null]